KURAClinical Trials•globenewswire•
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
Sentiment:Positive (70)
Summary
(NASDAQ:KURA) Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs)
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 16, 2025 by globenewswire